Portal de investigação
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era (Jan, 10.1007/s12325-021-01990-6, 2022)
Data de publicação:
Data Ahead of Print:
Autores da FMUP
Participantes de fora da FMUP
- Schreiber, S
- Ben-Horin, S
- Alten, R
- Westhovens, R
- Peyrin-Biroulet, L
- Danese, S
- Hibi, T
- Takeuchi, K
- An, Y
- Kim, DH
- Yoon, S
- Reinisch, W
Unidades de investigação
Abstract
In the original article, a few errors were by the publisher during the typesetting process. The Graphical Abstract has been updated and a few minor formatting corrections have been made. The original article has been corrected. © Springer Healthcare Ltd., part of Springer Nature 2022ss.
Dados da publicação
- ISSN/ISSNe:
- 0741-238X, 1865-8652
- Tipo:
- Correction
- Páginas:
- 2281-2281
- Link para outro recurso:
- www.scopus.com
Advances in Therapy Springer International Publishing AG
Citações Recebidas na Web of Science: 1
Citações Recebidas na Scopus: 1
Documentos
- Não há documentos
Filiações
Keywords
- erratum
Proyectos asociados
Gut microbiome and IBD therapy: an interplay?
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (GutIBD) . 2021
Iron deficiency and inflammatory bowel disease. Correlation with inflammation and Vitamin D status.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (IronIBD) . 2021
Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (4WARD) . 2021
Isolated Ulceration of Crohn’s Anastomosis
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Therapeutic Drug Monitoring: An Emergent Approach in Inflammatory Bowel Disease
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2019
Citar a publicação
Schreiber S,Ben S,Alten R,Westhovens R,Peyrin L,Danese S,Hibi T,Takeuchi K,Magro F,An Y,Kim DH,Yoon S,Reinisch W. Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era (Jan, 10.1007/s12325-021-01990-6, 2022). Adv. Ther. 2022. 39(5):p. 2281-2281. IF:3,800. (2).
